Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06469528
Other study ID # KCH23-187
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date June 24, 2024
Est. completion date October 5, 2026

Study information

Verified date June 2024
Source King's College Hospital NHS Trust
Contact Anne-Marie Murtagh
Phone +44 02032999000
Email qm.khpcto@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ESCALATE will provide a thorough investigation of how anti-inflammatory therapy, with low-dose colchicine, affects patients with stable coronary artery disease. Using traditional clinical risk factors and multimodality intracoronary imaging, the investigators will identify patients with the greatest clinical risk. Participants will undergo repeat multimodality intracoronary imaging assessment at 6 months to measure the impact once-daily low-dose colchicine therapy on the structure and function of coronary arteries. This study will provide valuable insights into how anti-inflammatory therapies, such as colchicine, may improve outcomes in patients with coronary artery disease.


Description:

1. Background and study aims Despite recent advances, coronary artery disease (CAD) remains the main cause of death worldwide. CAD occurs when the arteries bringing blood to the heart become narrowed by a build-up of fatty material within their walls. If this occurs gradually, it can cause chest discomfort i.e., angina. In a heart attack, the artery wall becomes inflamed and splits causing blood clot formation and an abrupt blockage of flow, resulting in severe pain and damaged heart muscle. Current treatments focus on reducing cholesterol, slowing the build-up of fatty material, and rapidly restoring blood flow during a heart attack. Chronic inflammation, acting in tandem with other risk factors, has been identified as playing a central role in CAD progression and its acute manifestations. Colchicine is a safe, well-tolerated, anti-inflammatory therapy used in the treatment of gout and other inflammatory conditions. Daily treatment with low-dose colchicine has proven effective in reducing rates of heart attack and death in large clinical trials, but use in routine practice remains low. A contributing factor to this reticence is uncertainty regarding the mechanism through which colchicine provides benefit. This study is designed to address this knowledge gap. 2. Who can participate? Patients aged 18 to 90 years old with coronary artery disease and high clinical risk 3. What does the study involve? Using traditional markers of clinical risk and state-of-the-art imaging from inside the coronary artery, the researchers will identify patients with CAD and the greatest clinical risk. Eligible patients, already established on statin therapy will be allocated to a six-month course of low-dose colchicine plus usual care, or usual care only. Researchers, participants, and usual clinicians will be aware of the allocation during the study. After 6 months, the researchers will assess the impact of colchicine on the appearance of individual coronary artery lesions, blood flow in the large and small blood vessels of the heart. This study will provide a detailed assessment of colchicine and its mechanism of action in CAD.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date October 5, 2026
Est. primary completion date October 5, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Ability to provide written informed consent 2. Age 18 to 90 years old 3. Male, or female of non-child-bearing potential 4. Elevated clinical risk, as evidenced by =1 of: - Previous spontaneous acute myocardial infarction (diagnosed according to the universal MI criteria) with or without persistent ST-segment elevation - Previous stroke or intervention for peripheral arterial disease (i.e., evidence of atherosclerotic disease affecting >1 vascular bed) - Established diagnosis of diabetes mellitus - Systemic Coronary Risk Estimation 2 (SCORE2) or Systemic Coronary Risk Estimation 2 - Older Persons (SCORE2-OP) algorithm 10-year risk of fatal and non-fatal myocardial infarction or stroke >10% 5. Documented evidence of coronary artery disease, with an angiographically moderate stenosis on invasive coronary angiography (30-80%) - At least one non-flow limiting (FFR >0.80) moderate lesion with TCFA (minimum fibrous cap thickness of less than or equal to120µm and lipid arc >90°) 6. History of prescribed statin therapy, at a stable dose, for >4 weeks 7. Evidence of residual inflammation at baseline (i.e., high-sensitivity CRP =2) Exclusion Criteria: 1. Women who are pregnant, breast feeding, or of child-bearing potential 2. Symptoms of unstable angina, characterised as: angina at rest; new onset of severe exertional angina (CCS grade III or higher for <4 weeks); or distinct, sudden, intensification of previously stable angina 3. Previous spontaneous acute myocardial infarction (diagnosed according to the universal MI criteria) with or without persistent ST-segment elevation <4 weeks from recruitment 4. Previous coronary artery bypass grafting 5. Known chronic total occlusion of coronary artery 6. Chronic kidney disease with eGFR <50 mL/min/1.73 m2 per MDRD formula or renal replacement therapy at baseline assessment 7. Known active or recurrent hepatic disorder (including cirrhosis, hepatitis B and hepatitis C, or confirmed ALT/AST levels > 3 times ULN or total bilirubin > 2 times ULN) at baseline assessment 8. Symptoms of severe heart failure (systolic or diastolic) with New York Heart Association (NYHA) Functional Classification 3 or 4 9. Moderate or severe valvular heart disease considered likely to require intervention 10. History of blood dyscrasia including anaemia, thrombocytopenia, neutrophilia, leukopenia or other abnormality of blood count at baseline 11. Peripheral neuritis, myositis or marked myo-sensitivity to statins 12. A history of alcohol and/or substance abuse that could interfere with the conduct of the trial 13. Patients with suspected or proven immunocompromised state, including: 1. those with evidence of Human Immunodeficiency Virus (HIV) infection; Patients on anti-retroviral therapy are excluded 2. those with any other medical condition which in the opinion of the investigator places the patient at unacceptable risk for participation in immunomodulatory therapy 14. History of hypersensitivity to the study drug or its constituents 15. Patients who have received an investigational drug or device within 30 days (inclusive) of baseline assessment, or who are expected to participate in any other investigational drug or device study during the conduct of this trial 16. Any biologic drugs targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab) 17. Established long-term pharmacotherapy with a strong CYP3A4 inhibitor or a P-glycoprotein inhibitor (P-gpi) (e.g., macrolide antibiotics, ciclosporin, ketoconazole, itraconazole, voriconazole, HIV protease inhibitors, verapamil, diltiazem and disulfiram) 18. Contraindications to intravenous adenosine will exclude patients from adenosine induced hyperaemia 19. Any life-threatening condition with life expectancy <6 months that might prevent the patient from completing the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Colchicine 0.5 MG
Low dose daily colchicine

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
King's College Hospital NHS Trust King's College London

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute change in minimal fibrous cap thickness The absolute change (µm) in minimal fibrous cap thickness, in a defined arterial region of interest, as assessed by OCT 6months
Secondary Major adverse clinical events Major adverse cardiovascular event (MACE): Composite of cardiovascular death, non-fatal MI, unplanned revascularisation and ischaemic stroke 6 months
Secondary Acute kidney injury AKI secondary to contrast induced nephropathy 6 months
Secondary Major bleeding events (BARC 3-5) Periprocedural major bleeding events (BARC 3-5) 6 months
Secondary Hospitalisation with serious infection Hospitalisation requiring intravenous antibiotics 6 months
Secondary % change in minimal fibrous cap thickness Percentage change in minimal fibrous cap thickness, as determined by OCT, in a defined arterial region of interest 6 months
Secondary % change in maximal lipid arc Percentage change in lipid arc, as determined by OCT, in a defined arterial region of interest 6 months
Secondary Percentage change in lipid index Percentage change in lipid index, as determined by OCT, in a defined arterial region of interest 6 months
Secondary Absolute change in maximum lipid core burden index in a 4-mm segment (maxLCBI4mm) Absolute change in maximum lipid core burden index in a 4-mm segment (maxLCBI4mm), as determined by NIRS, in a defined arterial region of interest 6 months
Secondary Relative change (%) in maximum lipid core burden index in a 4-mm segment (maxLCBI4mm) Relative change (%) in maximum lipid core burden index in a 4-mm segment (maxLCBI4mm), as determined by NIRS, in a defined arterial region of interest 6 months
Secondary Change in total atheroma volume Change in percent atheroma volume, as determined by IVUS, in a defined arterial region of interest 6 months
Secondary Absolute and percentage change in coronary flow reserve (CFR) Absolute and percentage change in coronary flow reserve (CFR), measured in artery of interest 6 months
Secondary Absolute and percentage change in index of microvascular resistance (IMR) Absolute and percentage change in index of microvascular resistance (IMR), measured in artery of interest 6 months
Secondary Absolute and percentage change in vessel fractional flow reserve (FFR) Absolute and percentage change in vessel fractional flow reserve (FFR), measured in artery of interest 6 months
Secondary Percentage change in high-sensitivity c-reactive protein (hs-CRP) Percentage change in high-sensitivity c-reactive protein (hs-CRP) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A